AKT1 and colonic neoplasm: Li et al. (2018) demonstrated that bazedoxifene (BZA) significantly enhances the antitumor effects of 5-fluorouracil (5-FU), a commonly used chemotherapeutic agent in colon cancer, by inhibiting the IL-6/GP130 signaling pathway and reducing the phosphorylation of STAT3, AKT, and ERK in colon cancer cells.